JP2003523721A5 - - Google Patents

Download PDF

Info

Publication number
JP2003523721A5
JP2003523721A5 JP2000591195A JP2000591195A JP2003523721A5 JP 2003523721 A5 JP2003523721 A5 JP 2003523721A5 JP 2000591195 A JP2000591195 A JP 2000591195A JP 2000591195 A JP2000591195 A JP 2000591195A JP 2003523721 A5 JP2003523721 A5 JP 2003523721A5
Authority
JP
Japan
Prior art keywords
cell
expression cassette
sequence
polypeptide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000591195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003523721A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/031273 external-priority patent/WO2000039304A2/en
Publication of JP2003523721A publication Critical patent/JP2003523721A/ja
Publication of JP2003523721A5 publication Critical patent/JP2003523721A5/ja
Pending legal-status Critical Current

Links

JP2000591195A 1998-12-31 1999-12-30 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 Pending JP2003523721A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11449598P 1998-12-31 1998-12-31
US60/114,495 1998-12-31
US15219599P 1999-09-01 1999-09-01
US60/152,195 1999-09-01
PCT/US1999/031273 WO2000039304A2 (en) 1998-12-31 1999-12-30 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2003523721A JP2003523721A (ja) 2003-08-12
JP2003523721A5 true JP2003523721A5 (enExample) 2007-03-01

Family

ID=26812259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000591195A Pending JP2003523721A (ja) 1998-12-31 1999-12-30 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用

Country Status (6)

Country Link
US (2) US7943375B2 (enExample)
EP (1) EP1141314A2 (enExample)
JP (1) JP2003523721A (enExample)
AU (1) AU2487300A (enExample)
CA (1) CA2358385C (enExample)
WO (1) WO2000039304A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU778106B2 (en) * 1999-04-26 2004-11-18 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
CN1423698A (zh) 1999-11-16 2003-06-11 真那特应用生物科技有限公司 Hiv-1亚型间(c/b’)基因组和其用途
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
ATE318908T1 (de) * 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
EP1425040A2 (en) * 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Hiv−gagのコドン最適化dnaワクチン
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2004032860A2 (en) 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
EP2019686B1 (en) 2006-03-31 2012-07-11 Novartis AG Combined mucosal and parenteral immunization against hiv
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
US8557533B2 (en) * 2007-02-01 2013-10-15 Helmut Jonuleit Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
MX2014005548A (es) 2011-11-14 2014-08-21 Novartis Ag Complejos inmunogenicos de carbomeros polianionicos y polipeptidos env y metodos de manufactura y usos de los mismos.
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602705A (en) 1981-11-09 1986-07-29 Lucas Industries Public Limited Company Flywheel mechanism for anti-skid braking systems
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US6610476B1 (en) 1984-08-22 2003-08-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of HIV-1 DNA
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
WO1986003224A1 (en) 1984-11-29 1986-06-05 Scripps Clinic And Research Foundation Polypeptides and antibodies related to deglycosylated viral glycoproteins
ATE138100T1 (de) 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
NZ215867A (en) 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
EP0245362B1 (en) 1985-10-24 1994-06-29 Ronald C. Kennedy Synthetic peptides and use for diagnosis and vaccination for aids and arc
EP0242216A1 (en) 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
AU7786387A (en) 1986-07-21 1988-02-10 Southwest Foundation For Biomedical Research Composition of matter and method of immunizing against viral causative agents of aids and arc
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
IL86832A (en) 1987-06-22 2002-09-12 Medeva Holdings Bv A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
WO1989002277A2 (en) 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0347435A4 (en) 1987-09-04 1991-11-21 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
US5879907A (en) 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5204259A (en) 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
CA1340748C (en) 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
WO1990002568A1 (en) 1988-09-13 1990-03-22 Chiron Corporation Hiv-1 envelope muteins lacking hypervariable domains
WO1990003984A1 (en) 1988-10-03 1990-04-19 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
AU5184190A (en) 1989-02-23 1990-09-26 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL93682A (en) 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
WO1990011359A1 (en) 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
WO1990012094A1 (en) 1989-04-05 1990-10-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A clone of double-stranded rna virus and applications thereof
EP0431128B1 (en) 1989-06-01 2003-03-26 Applied Biotechnology, Inc. Vector coding for self-assembled, defective, non-self-propagating viral particles
US5130247A (en) 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
AU6523590A (en) 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
DE69019291T2 (de) 1989-10-23 1995-09-21 F. Hoffmann-La Roche Ag, Basel Synthetische HTLV-I Hüll-Peptide.
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
AU6965591A (en) 1989-11-17 1991-06-13 Amgen, Inc. A method of detecting htlv-i antibodies in human body fluids
HUT60506A (en) 1989-11-20 1992-09-28 Oncogen Process for producing non-replicable, recombinant retrovirus particles and antiviral and immunogenic preparations
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
IE910779A1 (en) 1990-03-09 1991-09-11 Chiron Corp PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
US5876724A (en) 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
AU647108B2 (en) 1990-04-03 1994-03-17 Genentech Inc. Methods and compositions for vaccination against HIV
AU7676891A (en) 1990-04-03 1991-10-30 Genentech Inc. Hiv envelope polypeptides
IL97985A0 (en) 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
EP0551308A4 (en) 1990-08-29 1994-09-14 Us Health Novel peptide antigens and immunoassays, test kits and vaccines using the same
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
AU653366B2 (en) 1990-09-28 1994-09-29 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100090A (pt) 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
JPH06508821A (ja) 1991-03-07 1994-10-06 セラジュン インク ウイルス病治療のための細胞表面受容体を標的とする分子の使用
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
AU2412692A (en) 1991-07-23 1993-02-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel peptide antigens and immunoassays, test kits and vaccines using the same
US5558865A (en) 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
WO1993004090A1 (en) 1991-08-22 1993-03-04 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
DK0608261T3 (da) 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
EP0613378A1 (en) 1991-10-28 1994-09-07 Institut Pasteur Induction of protection against viral infection by synergy between viral proteins and viral peptides
AU3483293A (en) 1992-01-22 1993-09-01 New England Medical Center Hospitals, Inc., The Pathogen-specific CTL therapy
US5174666A (en) 1992-02-12 1992-12-29 Smith Corona Corporation Printing device having printwheel coupling means
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
WO1993021346A1 (en) 1992-04-09 1993-10-28 Abbott Laboratories Assay for detection of hiv antigen and hiv antibody
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
CA2105629A1 (en) 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5686078A (en) 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
ES2194015T3 (es) 1992-09-30 2003-11-16 Scripps Research Inst Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994016060A1 (en) 1993-01-11 1994-07-21 The Trustees Of The University Of Pennsylvania Mutants of hiv for supression of hiv infection
AU692433B2 (en) 1993-01-13 1998-06-11 Arsinur Burcoglu Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6140059A (en) 1993-01-16 2000-10-31 Schawaller; Manfred Methods for the obtention of human immunodeficiency virsus Type 1 envelope glycoproteins in native and oligomeric form employing recombinant chimeric antigens containing collagenase recognition sites.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ES2249760T3 (es) 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
WO1994018221A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
AU6359794A (en) 1993-03-05 1994-09-26 Genelabs Technologies, Inc. Method for hiv quantitation
NZ263373A (en) 1993-03-11 1997-05-26 Univ Southern California Monoclonal antibodies and use against immunoinfective cluster viruses
JP4108118B2 (ja) 1993-03-26 2008-06-25 ジェン−プローブ・インコーポレイテッド ヒト・免疫不全ウイルス1型の検出
US5869624A (en) 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
KR960701988A (ko) 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
WO1994028929A1 (en) 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
AU693098B2 (en) 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
CA2125344A1 (en) 1993-07-01 1995-01-02 Casey D. Morrow Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
ATE239787T1 (de) 1993-07-19 2003-05-15 Gen Probe Inc Oligonukleotide mit wirkung gegen den menschlichen immunodefiziens-virus
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
CA2174532A1 (en) 1993-10-19 1995-04-27 Carlos F. Barbas Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
JPH09504296A (ja) 1993-10-26 1997-04-28 シンテロ インコーポレイテッド Hiv粘膜感染の阻止
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
CA2185129A1 (en) 1994-03-14 1995-09-21 Angeline Douvas Methods to diagnose and treat hiv-1 infection
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
DE69527708T2 (de) 1994-04-29 2003-04-30 Duke University, Durham Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
WO1995033206A1 (en) 1994-05-31 1995-12-07 Abbott Laboratories Detection of different hiv genotypes utilizing a synthetic peptide-modified immunoassay
WO1995033835A1 (en) 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5733781A (en) 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US5955342A (en) 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996009066A2 (en) 1994-09-23 1996-03-28 The Johns Hopkins University School Of Medicine Method of treatment of human immunodeficiency virus (hiv) infection
MX9703676A (es) 1994-11-17 1998-03-31 Maxim Pharm Inc Inmunogenos para estimular la inmunidad de las mucosas.
US5550280A (en) 1994-11-30 1996-08-27 Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee Hindered aromatic ester compounds useful as anti-viral agents
JPH10512243A (ja) 1994-12-30 1998-11-24 カイロン コーポレイション 遺伝子送達ビヒクルの非外傷性投与
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
FR2730411B1 (fr) 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
WO1997003198A2 (en) 1995-07-07 1997-01-30 Texas A & M University System Nucleotide and amino acid sequence and uses thereof
WO1997011605A1 (en) 1995-09-28 1997-04-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
AU1750497A (en) 1996-01-17 1997-08-11 Progenics Pharmaceuticals, Inc. Compounds capable of inhibiting hiv-1 infection
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6087486A (en) 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US5649652A (en) 1996-02-16 1997-07-22 Sackett; Eleanor L. Clothes hanger with storage hook
ATE309366T1 (de) * 1996-02-22 2005-11-15 Merck & Co Inc Synthetische hiv-gene
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU728422B2 (en) 1996-06-21 2001-01-11 Merck & Co., Inc. Vaccines comprising synthetic genes
US5951975A (en) 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
EP0942747A1 (en) 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
CA2265889A1 (en) 1996-09-06 1998-03-12 The Regents Of The University Of California E25a protein, methods for production and use thereof
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US5830697A (en) 1997-01-21 1998-11-03 The Board Of Trustees Of The Leland Stanford Junior University P-glycoprotein mutant resistant to cyclosporin modulation
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU6535898A (en) 1997-03-14 1998-10-12 President And Fellows Of Harvard College Glycosylation deficient siv and hiv envelope glycoproteins
RO120148B1 (ro) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
JP2001519070A (ja) 1997-03-24 2001-10-16 クイーンズ ユニバーシティー アット キングストン 一致検出の方法、製品および装置
AU754242B2 (en) 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5858675A (en) 1997-05-13 1999-01-12 Incyte Pharmaceuticals, Inc. Double-stranded RNA-binding protein
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
AU8160298A (en) 1997-06-23 1999-01-04 Emory University Human immunodeficiency viruses causing aids in a nonhuman primate
CA2296067C (en) 1997-07-09 2008-10-07 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
CA2298438C (en) 1997-08-01 2010-10-05 Genetic Systems Corporation Synthetic antigen for the detection of antibodies immunoreactive with hiv virus
WO1999012416A1 (en) 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
EP1028712B1 (en) 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
US5932442A (en) 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
CA2320513A1 (en) 1998-02-11 1999-08-19 Joseph T. Bruder Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
WO1999053046A2 (en) 1998-04-14 1999-10-21 Chiron Corporation Noncloning technique for expressing a gene of interest
CA2328180A1 (en) 1998-04-14 1999-10-21 Merck & Co., Inc. Needleless administration of polynucleotide formulations
ATE315653T1 (de) 1998-04-22 2006-02-15 Chiron Corp Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
FR2780069B1 (fr) 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
BR9912732A (pt) 1998-08-03 2001-11-27 Univ Montana Estrutura molecular isolada, vìrus envelopadorecombinante, formilação de vacina, anticorpomonoclonal, anti-soro policlonal, geléia, espuma,creme ou unguento contraceptivo, amostras desangue de mamìfero e de humano, kit, linhagemcelular, processos de tratamento ou deprevenção de infecção por um vìrus em sujeito, detratamento ou de prevenção de infecção por hivem um humano, de inibição de infecção por um vìrusem uma amostra de sangue, de inibição de infecçãopor hiv em uma amostra de sangue humano, dedescontaminação de ferramentas cirúrgicas oudentais, de monitoração de produto de anticorpopara a estrutura molecular, de produção de umimunógeno para uso em uma vacina para otratamento ou a prevenção de infecção por umvìrus, e de produção de um imunólogeno para usoem uma vacina para o tratamento ou a prevençãode infecção por hiv, estrutura reticulada,anticorpo monoclonal para a estrutura, dedescontaminação de ferramentas cirúrgicas oudentais, processo de seleção de uma estruturamolecular para eficácia de vacina, mamìfero,complexo de proteìna isolado, formulação devacina, processos de imunização de um animal paraum vìrus, e de preparação de um complexo deproteìna, células fixadas, processos depurificação de um complexo de proteìna e detratamento de um hospedeiro que tem sidoexposto a um vìrus, ou de prevenção de infecçãode um hospedeiro pelo citado vìrus, e composição.
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
AU5980899A (en) 1998-09-25 2000-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
CA2344558A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6489542B1 (en) 1998-11-04 2002-12-03 Monsanto Technology Llc Methods for transforming plants to express Cry2Ab δ-endotoxins targeted to the plastids
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2360352A1 (en) 1999-01-27 2000-08-03 Stratagene Methods and compositions for high level expression of a heterologous protein with poor codon usage
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
AU778106B2 (en) 1999-04-26 2004-11-18 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
MXPA01011137A (es) 1999-05-03 2003-07-14 Uab Research Foundation Inmunizacion genetica no invasiva, productos de la expresion a partir de esta, y sus usos.
AP1891A (en) 1999-05-06 2008-09-23 The Immune Response Corp HIV immunogenic compositions and methods.
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US6280989B1 (en) 1999-06-17 2001-08-28 Dmitri Kapitonov Sialyltransferases
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド gag遺伝子保有アデノウイルスHIVワクチン
US7479285B1 (en) 1999-08-19 2009-01-20 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
CA2392010A1 (en) 1999-08-27 2001-03-08 Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
WO2001019958A2 (en) 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
CA2384828A1 (en) 1999-09-21 2001-03-29 Zivko Nikolov Methods for producing recombinant proteins
ATE454901T1 (de) 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
CA2387646A1 (en) 1999-10-21 2001-04-26 Kalobios, Inc. A general method for optimizing the expression of heterologous proteins
EP1228237A1 (en) 1999-11-01 2002-08-07 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
KR20020059727A (ko) 1999-11-13 2002-07-13 플레믹 크리스티안 고차 핵산 기재 구조
WO2001042308A2 (en) 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
AU782193B2 (en) 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
WO2001045748A1 (en) 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
JP4627950B2 (ja) 1999-12-23 2011-02-09 アメリカ合衆国 変異HIVgag/pol、SIVgagおよびSIVenv遺伝子を持つ分子クローン
DK1240186T3 (da) 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
AU2001233063A1 (en) 2000-01-31 2001-08-07 Aaron Diamond Aids Research Center Vaccination of hiv infected persons following highly active antiretroviral therapy
JP2003529559A (ja) 2000-01-31 2003-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規用途
AU2001238501A1 (en) 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
CA2402440A1 (en) 2000-02-18 2001-08-23 University Of Washington Aids ancestral viruses and vaccines
US20030138453A1 (en) 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
JP2004502445A5 (enExample)
CA2452015A1 (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP2002533124A5 (enExample)
CA2360347A1 (en) Improved expression of hiv polypeptides and production of virus-like particles
AU641211B2 (en) Vaccines
US6190666B1 (en) DNA expression systems based on alphaviruses
JPH09322781A5 (enExample)
JP2002539793A5 (enExample)
KR870008030A (ko) 색소 세포종에 대한 왁진
EP0330191A3 (en) DNA encoding CD40
JP2002510494A5 (enExample)
JP2009082136A5 (enExample)
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
WO1992001049A3 (en) Cd53 cell surface antigen and use thereof
CA2385325A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
JP2002542827A5 (enExample)
JP2002533125A5 (enExample)
WO2000068266A1 (en) Amyloid precursor protein protease and related nucleic acid compounds
EP2281832A2 (en) Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
CA2389206A1 (en) Activation of hcv-specific t cells
JP2005521380A5 (enExample)
CA2358915A1 (en) Modified hiv env polypeptides
CA2215328A1 (en) Novel human cytomegalovirus dna sequences
CA2135278A1 (en) Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus
PL375740A1 (en) Recombinant poxvirus comprising at least two cowpox ati promoters